ABSTRACT
Insulin is the cornerstone of pharmacotherapy for the estimated 0.73 to 1.46 million persons with type 1 diabetes mellitus (DM1) in the United States. While the peak incidence of DM1 is around the time of puberty, about 25% of cases will present after 35 years of age (1). As progressively more aggressive targeted glycemic, blood pressure, and LDL cholesterol treatment strategies impact both microvascular and macrovascular diabetes complications and comorbidities, there is an ever increasing need for effective insulin therapy strategies for treatment of the individual with DM1. In conjunction with lifestyle and self-care management, meticulous attention, by both the patient and the health-care provider, to the insulin regimen prescribed through the use of either multiple daily insulin (MDI) dosing or a continuous subcutaneous insulin infusion (CSII) pump will enable attainment of HbA1c and blood glucose (BG) targets.
